Business Acquisition
Aurobindo Pharma Completes Acquisition of Lannett Company in the U.S.
NSE
auropharma
BSE
524804
Aurobindo Pharma Limited announced the successful completion of the acquisition of Lannett Company, Inc. by its wholly owned U.S. subsidiary, Aurobindo Pharma USA Inc. (APUSA). The acquisition became effective on June 29, 2026, following regulatory approval from the U.S. Federal Trade Commission, with Lannett now operating as Lannett Company LLC.
PRICE-SENSITIVE TRIGGER
Event: Completion of the acquisition of Lannett Company by Aurobindo Pharma USA Inc.
Type: Business Acquisition
Impact: Positive
Immediate Effect: Lannett has officially become a wholly owned subsidiary of APUSA. Integration activities have commenced immediately, expanding Aurobindo’s U.S. manufacturing and pharmaceutical capabilities while strengthening its workforce and operational scale.
highlight:
- The acquisition has been successfully completed, and Aurobindo will integrate more than 400 Lannett employees into its U.S. operations.
What Happened ?
Aurobindo Pharma USA Inc. (APUSA), the wholly owned U.S. subsidiary of Aurobindo Pharma Limited, has completed the acquisition of Lannett Company, Inc. following clearance from the U.S. Federal Trade Commission on June 18, 2026.
Effective June 29, 2026, Lannett has become a wholly owned subsidiary of APUSA and will operate under the name Lannett Company LLC. The company stated that integration activities will begin immediately while ensuring uninterrupted supply of essential medicines and continuity of customer and partner relationships.
Key Details
Acquisition Completion & Integration:
- Acquisition of Lannett Company has been successfully completed.
- Regulatory approval was received from the U.S. Federal Trade Commission.
- Effective date of acquisition is June 29, 2026.
- Lannett will now operate as Lannett Company LLC.
- Integration activities have commenced immediately following completion.
- Aurobindo intends to maintain uninterrupted access to critical medicines during the transition.
- Existing customer, supplier and stakeholder relationships will continue to be supported.
- More than 400 Lannett employees will join the APUSA organization.
- The acquisition is expected to strengthen operational capabilities and talent resources within Aurobindo’s U.S. business.
Note:
- The announcement marks the formal completion of a previously announced transaction and represents the beginning of operational integration rather than the announcement of a new acquisition proposal.
Risk Analysis
Summary:
- The acquisition is complete, but successful realization of long-term benefits depends on efficient post-merger integration, operational continuity, employee retention, and execution of business synergies.
Key Risks:
- Integration of operations may require time before expected synergies are realized.
- Retaining key employees and maintaining customer relationships remain important.
- Any disruption during operational integration could temporarily affect execution.
- Realization of strategic benefits depends on successful execution of integration plans.
Worst Case:
- Delays or operational challenges during integration could postpone synergy realization and reduce the expected strategic value of the acquisition.
Risk Level: Medium
Company Commentary
- The company confirmed that the acquisition has been successfully completed after receiving U.S. regulatory approval.
- Management stated that integration will prioritize uninterrupted availability of critical medicines.
- Aurobindo intends to combine capabilities and resources to enhance the availability of essential medicines.
- The company believes the transaction will create sustainable long-term value for patients, customers and stakeholders.
- Management welcomed more than 400 Lannett employees into the organization and acknowledged the contribution of Lannett’s management team in ensuring a smooth transition.
Official Exchange Filing: Aurobindo Pharma Limited
